Shattuck Labs

Shattuck Labs, Inc. engages in the research and development of dual-sided fusion proteins used for medical treatment of cancer and autoimmune disease. It primarily focuses on Agonist Redirected Checkpoint (ARC) and Gamma Delta T Cell Engagers (GADLEN) platforms. It develops a novel class of biologic medicines, capable of multifunctional activity, with potential applications in oncology and autoimmune diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Shattuck Labs reports Q4 losses, optimistic for 2023 advancements

Shattuck Labs showcased progress with lead program 154 and a strong financial position.
Challenges include discontinued program SL-279252 and financial losses in 2022.
Opportunities lie in ongoing clinical trials, differentiation between programs, and optimism for 2023.

Shattuck Labs reports promising Q3 results and eyes future milestones

Shattuck Labs (STTK) showcased progress with SL-172154 in Q3 2023, reporting promising clinical data and a strong financial position. While facing challenges of ongoing losses, the company's unique mechanism of action and upcoming milestones present opportunities for growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Los Angeles, California--(Newsfile Corp. - December 3, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Shattuck Labs, Inc. ("Shattuck" or "the Company") (NASDAQ: STTK) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Shattuck released its results for the third quarter of 2021 on...

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Shattuck Labs, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

AUSTIN, TX and DURHAM, NC, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced its presentation at the TIGIT Therapies Digital Summit 2021 being held virtually December 7 – 9, 2021.

Shattuck Labs to Present at TIGIT Therapies Digital Summit 2021

NEW YORK, Dec. 1, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Shattuck Labs, Inc. (NASDAQ: STTK) resulting from allegations that Shattuck may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Shattuck securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

STTK BREAKING NEWS: ROSEN, A LEADING NATIONAL FIRM, Encourages Shattuck Labs, Inc. Investors with Losses to Inquire About Class Action Investigation - STTK

LOS ANGELES--(BUSINESS WIRE)---- $STTK #STTK--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Shattuck Labs, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Shattuck Labs, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $STTK #STTK--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Shattuck Labs, Inc.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Shattuck Labs, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Shattuck Labs, Inc. (NASDAQ: STTK) resulting from allegations that Shattuck may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Shattuck securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangemen

EQUITY ALERT: Rosen Law Firm Encourages Shattuck Labs, Inc. Investors with Losses to Inquire About Class Action Investigation – STTK

– SL-279252 (PD1-Fc-OX40L) demonstrates anti-tumor activity and evidence of dose-dependent immune activation in heavily pretreated, checkpoint experienced patients –

Shattuck Labs Announces Preliminary Clinical Data from Ongoing Phase 1 Clinical Trials of ARC Fusion Proteins SL-172154 and SL-279252

– Announced initial Phase 1 dose-escalation data from SL-172154 in ovarian cancer and SL-279252 in solid tumors at the Society for Immunotherapy of Cancer (SITC) annual meeting; both clinical trials remain ongoing –

Shattuck Labs Reports Third Quarter 2021 Financial Results and Recent Business Highlights

– Event scheduled for Friday, November 12, 2021 at 8:00 a.m. ET –

Shattuck Labs to Host Conference Call and Webcast Highlighting Data Presented at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

AUSTIN, TX and DURHAM, NC, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease with three ongoing Phase 1 clinical trials, today announced that company management will participate in four virtual investor conferences in November 2021.

Shattuck Labs Announces Participation in Upcoming November Investor Conferences

Shattuck Labs appoints new Board member, Dr. Carrie Brownstein, M.D.; Dr. George Golumbeski, Ph.D., appointed as Chairman of the Board Shattuck Labs appoints new Board member, Dr. Carrie Brownstein, M.D.; Dr. George Golumbeski, Ph.D., appointed as Chairman of the Board

Shattuck Labs Announces Changes to its Board of Directors

AUSTIN, TX and DURHAM, NC, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will present four posters at SITC's 36th Annual Meeting being held Wednesday, November 10, 2021 to Sunday, November 14, 2021.

Shattuck Labs to Present Clinical Data on SL-172154 and SL-279252 and Preclinical Data on SL-9258 at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Shattuck Labs' (STTK) CEO Taylor Schreiber on Q2 2021 Results - Earnings Call Transcript

– Announced submission of abstracts for the initial Phase 1 dose-escalation data from both SL-172154 in ovarian cancer and SL-279252 in advanced solid tumors for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2021 –

Shattuck Labs Reports Second Quarter 2021 Financial Results and Upcoming Phase 1 Dose Escalation Data for SL-172154 and SL-279252

AUSTIN, TX and DURHAM, NC, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the BTIG Biotechnology Conference being held virtually August 9-10, 2021.

Shattuck Labs Announces Participation in the BTIG Biotechnology Conference

AUSTIN, TX and DURHAM, NC, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2021 on Wednesday, August 11, 2021, at 4:30 p.m. ET.

Shattuck Labs to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 11, 2021

AUSTIN, TX and DURHAM, NC, June 01, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the appointment of Abhinav A. Shukla, Ph.D., as Chief Technical Officer.

Shattuck Labs Appoints Abhinav A. Shukla as Chief Technical Officer

– Initial dose-escalation data from Phase 1 clinical trial for lead wholly owned CD47 checkpoint inhibitor, SL-172154 (SIRPα-Fc-CD40L), expected in the second half of 2021 –

Shattuck Labs Reports First Quarter 2021 Financial Results and Recent Business Highlights

AUSTIN, TX and DURHAM, NC, April 30, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer, will participate in two upcoming conferences.

Shattuck Labs Announces Participation in Upcoming May Conferences

AUSTIN, Texas and DURHAM, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the 7th Annual Truist Securities Life Sciences Summit being held virtually May 4-5, 2021.

Shattuck Labs Announces Participation in the 7th Annual Truist Securities Life Sciences Summit

AUSTIN, TX and DURHAM, NC, April 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in Needham's 20th Annual Healthcare Conference being held virtually April 12-15, 2021.

Shattuck Labs Announces Participation in Needham's 20th Annual Healthcare Conference

Adicet Bio, Inc.

Editas Medicine

Immatics NV

Sesen Bio Inc.

Sanofi

LAVA Therapeutics has filed to raise $101 million in an IPO.

LAVA Therapeutics Seeks $101 Million U.S. IPO

AUSTIN, TX and DURHAM, NC, March 16, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced the promotion of Andrew R. Neill to Chief Financial Officer from Vice President of Finance and Corporate Strategy.

Shattuck Labs Announces Promotion of Andrew R. Neill to Chief Financial Officer

Shattuck Labs Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

AUSTIN, TX and DURHAM, NC, March 11, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that two posters have been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, which is being held virtually April 10-15, 2021. The first poster will highlight preclinical data from the company's GADLEN™ platform, while the second will highlight preclinical data from the development of an in vivo model of checkpoint acquired resistance and the therapeutic potential of SL-9258 (TIGIT-Fc-LIGHT), derived from the company's ARC® platform, in an acquired resistance setting.

News for Shattuck Labs Stock (STTK)